Literature DB >> 18790236

Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy.

G H Luo1, Y P Lu, J Song, L Yang, Y J Shi, Y P Li.   

Abstract

AIM: Connective tissue growth factor (CTGF) is a highly profibrogenic molecule implicated in renal fibrogenesis. Small interfering RNA (siRNA) is an effective tool to silence gene expression. This study determined whether caudal vein injection of siRNA targeting CTGF inhibited its expression in rat kidneys in vivo, and furthermore whether it protected the kidney from renal fibrosis in chronic allograft nephropathy (CAN).
METHODS: Male inbred Fischer (F344, RT1(lv1)) rat renal grafts were orthotopically transplanted into Lewis (LEW, RT1(1)) rats following the procedure of Kamada with our modification. At 6 weeks, recipients were divided into siRNA, normal saline (NS), and control siRNA groups, using daily siRNA-targeting CTGF (0.1 mg/kg), or NS, or a control siRNA via caudal vein injection for 14 days. At 4, 6, and 8 weeks, we observed the pathologic changes, expression of CTGF, E-cadherin, collagen I and IV, and anti-smooth muscle actin (alpha-SMA).
RESULTS: Serum creatinine level, Banff score, and the expression of CTGF were significantly lower among the siRNA than the NS or the control siRNA groups at 8 weeks (P < .05). The expressions of collagen I and IV, and alpha-SMA were also significantly downregulated and E-cadherin was lost in the siRNA versus the NS and control siRNA groups at 8 weeks.
CONCLUSIONS: This study showed that delivery of CTGF siRNA via the caudal vein significantly inhibited expression of CTGF in rat kidneys, effectively preventing fibrosis in CAN. The results suggest that siRNA-targeting of CTGF has the potential to be a novel strategy for amelioration of CAN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790236     DOI: 10.1016/j.transproceed.2008.07.100

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  20 in total

Review 1.  Anti-fibrosis therapy and diabetic nephropathy.

Authors:  Anil Karihaloo
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

Review 2.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

3.  Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts.

Authors:  Galina S Bogatkevich; Anna Ludwicka-Bradley; Richard M Silver
Journal:  Arthritis Rheum       Date:  2009-11

Review 4.  Remedial applications of silencing ribonucleic acids and modalities for its delivery to the kidneys--a review.

Authors:  Dongjie Wang; Yanfen Lv; Huifang Zhu; Guifeng Lv; Jiyi Huang
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-06-04

Review 5.  New pharmacological treatments for improving renal outcomes in diabetes.

Authors:  Anne-Emilie Declèves; Kumar Sharma
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

Review 6.  Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies.

Authors:  António Nogueira; Maria João Pires; Paula Alexandra Oliveira
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

Review 7.  Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease.

Authors:  Helena M Kok; Lucas L Falke; Roel Goldschmeding; Tri Q Nguyen
Journal:  Nat Rev Nephrol       Date:  2014-10-14       Impact factor: 28.314

Review 8.  Fibrogenesis in kidney transplantation: potential targets for prevention and therapy.

Authors:  Arjang Djamali; Millie Samaniego
Journal:  Transplantation       Date:  2009-11-27       Impact factor: 4.939

Review 9.  Therapeutic targets for treating fibrotic kidney diseases.

Authors:  So-Young Lee; Sung I Kim; Mary E Choi
Journal:  Transl Res       Date:  2014-08-13       Impact factor: 7.012

10.  Connective tissue growth factor hammerhead ribozyme attenuates human hepatic stellate cell function.

Authors:  Run-Ping Gao; David R Brigstock
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.